Phase 4 Breast Cancer Trial, Not Yet Recruiting NCT07344974 Sponsor: Peking University Cancer Hospital & Institute Condition: Breast Cancer
Back to Breast Cancer

Phase 4 Breast Cancer Trial, Not Yet Recruiting

NCT07344974
Not Yet Recruiting Phase 4

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • A person must have breast cancer that has been confirmed through laboratory testing of tissue samples.
  • A person must have developed nerve-related side effects (such as tingling, numbness, or pain) of at least a mild level after receiving a chemotherapy treatment that includes a drug from the taxane family, and must have continued that treatment for at least two more cycles after those side effects appeared.
  • A person must be aged 18 or older, of any gender.
  • A person must have a good general level of physical functioning, meaning they are fully active or able to carry out light work (confirmed by a score of 0 or 1 on a standard medical scale called the ECOG scale).
  • A person must have heart, liver, kidney, and bone marrow function within acceptable ranges, based on blood tests taken within the 7 days before starting treatment, including: a haemoglobin level of at least 90 g/L (without having had a blood transfusion in the past 14 days); a neutrophil count of at least 1.5 × 10⁹/L; a platelet count of at least 75 × 10⁹/L; total bilirubin no higher than 1.5 times the upper limit of normal; liver enzyme levels (ALT and AST) no higher than 2.5 times the upper limit of normal; and kidney function within acceptable limits based on creatinine levels or a clearance rate of at least 60 mL/min.
  • A person must have an estimated life expectancy of at least 6 months.
  • A person must have read and signed a consent form agreeing to take part in the trial.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who already have a nerve condition, whether affecting the peripheral nerves (outside the brain and spinal cord) or the central nervous system (brain and spinal cord), before starting the trial.
  • People who have a known allergy to any ingredient in the investigational traditional Chinese medicine formula being studied.
  • People whose nerve symptoms are caused by an imbalance of salts or minerals in the body, diabetes, or another metabolic condition.
  • People whose nerve symptoms are caused by physical pressure on a nerve from any source.
  • People who are currently using other treatments intended to protect or support nerve health, such as nerve growth factor, vitamin B supplements, or calcium-magnesium preparations.
  • Women who are pregnant or currently breastfeeding.
  • People who have cognitive difficulties or a psychiatric condition.
  • People who have any other condition that the trial doctor considers makes participation unsuitable (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Phone: +86-010-88196380

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 4
Sponsor
Peking University Cancer Hospital & Institute
Registry
ClinicalTrials.gov
Start date
1 February 2026
Est. completion
1 February 2027

Primary endpoints

Proportion of Participants With Controlled Peripheral Neurotoxicity at Week 6 as Assessed by CTCAE v5.0; Proportion of Participants With Controlled Peripheral Neurotoxicity at Week 6 Assessed by the MD Anderson Symptom Inventory-Traditional Chinese Medicine Module (MDASI-TCM); Proportion of Participants With Controlled Peripheral Neurotoxicity at Week 6 as Assessed by Total Neuropathy Score-Clinical Version (TNSc)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov